1. Aplastic Anemia & Myelodysplastic Syndromes International Foundation, Inc. - Ser Aplastic Anemia MDS (myelodysplastic syndromes) International Foundation, Inc. serves as a resource directory for patient assistance and emotional support; provides educational materials and http://www.aplastic.org/

In The News - Updates on diseases and treatments. Frequently Asked Questions Want to Talk? - Network with other patients and families. Enroll in our Patient Registry to help researchers compile data on these diseases Merchandise Purchases help Fight AA and MDS Collaborative Clinical Trials Study Group You are Visitor No: P.O. Box 613 Annapolis, Maryland 21404-0613 USA Tel: 800.747.2820 Fax 410.867.0240 E-Mail help@aamds.org We subscribe to the HONcode principles of the Health On the Net Foundation This site was selected for inclusion in Current Web Contents , published by ISI (Institute for Scientific Information); and MedlinePlus Health Information , published by NLM (National Library of Medicine). Site designed, marketed and maintained by

2. Myelodysplastic Syndromes - Leukaemia Research Fund Booklet booklet. myelodysplastic syndromes. What are the myelodysplastic syndromes? There are five forms of myelodysplastic syndrome Refractory http://dspace.dial.pipex.com/lrf-/diseases/mds_book.htm

home patient information myelodysplastic syndromes myelodysplastic syndromes patient booklet Myelodysplastic Syndromes The booklets in this series are intended to provide general information about the diseases they describe. In many cases the treatment of individual patients will differ from that described in the booklets. At all times patients should rely on the advice of their specialist who is the only person with full information about their diagnosis and medical history. Causes Types of myelodysplastic syndrome Signs and symptoms Diagnosis ... Prognosis What are the myelodysplastic syndromes? There are five forms of myelodysplastic syndrome: Refractory anaemia Refractory anaemia with ring sideroblasts Refractory anaemia with excess blasts Refractory anaemia with excess blasts in transformation Chronic myelomonocytic leukaemia The myelodysplastic syndromes (MDS) are a group of diseases in which the production of blood cells is severely disrupted. The term myelodysplasia may be used to refer to the effects of myelodysplastic syndrome on the bone marrow. In contrast to leukaemia in which one type of blood cell is produced in excessively large numbers the production of any, and sometimes of all, types of blood cells is affected in myelodysplastic syndrome. The poor quality of the blood cells produced means that a significant proportion of them are destroyed before they leave the bone marrow. This means that the levels of red cells, white cells and platelets in the blood may be abnormally low. When the levels of all types of blood cells are low the condition is called pancytopaenia.

3. THE MYELODYSPLASTIC SYNDROMES FOUNDATION May 19, 2004 FDA approves Pharmion s Vidaza™ (azacitidine for injectable suspension) for the Treatment of myelodysplastic syndromes (MDS). http://www.mds-foundation.org/

IN MEMORIUM The MDS Foundation is a multi disciplinary, international organization devoted to the prevention, treatment, and study of the myelodysplastic syndromes. The organization is based upon the premise that international cooperation will accelerate the process leading to the control and cure of these diseases. First drug approved for the treatment of MDS should be commercially available within several weeks. For more information, see News Release at Pharmion's website at www.pharmion.com Alan F. List, MD Director, Hematologic Malignancies Program Tampa, FL Click here for full story and video on Ivanhoe Broadcast News PATIENTS: YOUR HELP IS NEEDED! Please join us in this most important endeavor. Click here to email your contact information. Patient Symposia Are Being Established by the MDS Foundation Click here for More Information Patient Advocacy Groups Are Being Established by the MDS Foundation The MDS Foundation has been working to develop a strategy for setting up patient groups nationwide. We have now completed this process and would like to have your help.

4. National Cancer Institute - Myelodysplastic Syndromes Treatment . What are myelodysplastic syndromes?...... Date Last Modified 06/06/2003, health professional. myelodysplastic syndromes. return to top. http://www.nci.nih.gov/cancerinfo/pdq/treatment/myelodysplastic/patient/

var bSearchBoxBool=false; window.onload+="MM_preloadImages('/images/nav_home_over.gif','/images/nav_cancer_topics_over.gif','/images/nav_clinical_trials_over.gif','/images/nav_cancer_statistics_over.gif','/images/nav_research_funding_over.gif','/images/nav_news_over.gif','/images/nav_about_over.gif');" Date Last Modified: Description Stage Explanation Treatment Option Overview De Novo Myelodysplastic Syndrome Secondary Myelodysplastic Syndrome ... Print-friendly Quick Links Dictionary Funding Opportunities NCI Publications NCI Calendar NCI Highlights Some Men with Low PSAs Have Prostate Cancer Energy Balance Trans-HHS Cancer Health Disparities Report Past Highlights Description What are myelodysplastic syndromes? What are myelodysplastic syndromes? Myelodysplastic syndromes, also called pre-leukemia or “smoldering” leukemia, are diseases in which the bone marrow does not function normally and not enough normal blood cells are made. The bone marrow is the spongy tissue inside the large bones in the body. The bone marrow makes red blood cells (which carry oxygen and other materials to all tissues of the body), white blood cells (which fight infection), and platelets (which make the blood clot). Normally, bone marrow cells called blasts develop (mature) into several different types of blood cells that have specific jobs in the body. Myelodysplastic syndromes occur most often in older people, but they can occur in younger people. The most common sign is anemia, which means there are too few mature red blood cells to carry oxygen. There may also be too few white blood cells in the blood to fight infections. If the number of platelets in the blood is lower than normal, this may cause people to bleed or bruise more easily. A doctor should be seen if a person bleeds without any reason, bruises more easily than normal, has an infection that won’t go away, or feels tired all the time.

5. National Cancer Institute - Myelodysplastic Syndromes Treatment myelodysplastic syndromes (PDQ®) Treatment. Two versions of this document are available The myelodysplastic syndromes (MDS) are a group of disorders characterized by 1 or more http://www.nci.nih.gov/cancerinfo/pdq/treatment/myelodysplastic/healthprofession

var bSearchBoxBool=false; window.onload+="MM_preloadImages('/images/nav_home_over.gif','/images/nav_cancer_topics_over.gif','/images/nav_clinical_trials_over.gif','/images/nav_cancer_statistics_over.gif','/images/nav_research_funding_over.gif','/images/nav_news_over.gif','/images/nav_about_over.gif');" Date Last Modified: General Information Classification Treatment Option Overview De Novo Myelodysplastic Syndrome Secondary Myelodysplastic Syndrome ... Print-friendly Quick Links Dictionary Funding Opportunities NCI Publications NCI Calendar NCI Highlights Some Men with Low PSAs Have Prostate Cancer Energy Balance Trans-HHS Cancer Health Disparities Report Past Highlights General Information The myelodysplastic syndromes (MDS) are a group of disorders characterized by 1 or more peripheral blood cytopenias secondary to bone marrow dysfunction. The syndromes may arise de novo, or secondarily after treatment with chemotherapy and/or radiation therapy for other diseases. Secondary myelodysplasia usually has a poorer prognosis than does de novo myelodysplasia. Prognosis is directly related to the number of bone marrow blast cells and to the degree of peripheral blood cytopenias. The MDS transform to acute myeloid leukemia (AML) in about 30% of patients after various intervals from diagnosis, and at variable rates (refer to the Cellular Classification section for more information). The acute leukemic transformation is much less responsive to chemotherapy than is de novo AML. Prognosis is also related to the type of myelodysplastic syndrome. Supportive care has been the mainstay of treatment. Judicious use of platelet and blood transfusions and iron chelation may prevent or delay alloimmunization and iron overload, and favorably affect prognosis.

6. Myelodysplastic Syndromes A description of what these diseases are, alternate names, and links for both patient and professional information. http://dspace.dial.pipex.com/lrf-/diseases/mds.htm

home patient information myelodysplastic syndromes Myelodysplastic syndromes Leukaemia Research Fund produces a booklet on The Myelodysplastic Syndromes, which provides general information on the disease. To download this booklet as a PDF click here . To view a copy of this booklet click here Useful links for health professionals Patient publications on the web Reviews Key information Teaching aids ... Scientific meetings The myelodysplastic syndromes (MDS) are a group of diseases in which the production of blood cells is severely disrupted. The term myelodysplasia may be used to refer to the effects of myelodysplastic syndrome on the bone marrow. In contrast to leukaemia in which one type of blood cell is produced in excessively large numbers the production of any, and sometimes of all, types of blood cells is affected in myelodysplastic syndrome. Synonyms: Refractory Anaemia; Preleukaemia; Chronic Myelomonocytic Leukaemia

7. Myelodysplastic Syndromes April 8, 2004. myelodysplastic syndromes CMEAuthors Razelle Kurzrock, MD; Moshe Talpaz, MD; Fan Zhang, MD. Disclosures. Release Date February 1, 2001; Valid for credit through January 31, 2003. This activity has expired. http://www.medscape.com/viewprogram/115

Register Log In June 2, 2004 Myelodysplastic Syndromes CME Authors: Razelle Kurzrock, MD; Moshe Talpaz, MD; Fan Zhang, MD Disclosures Release Date: February 1, 2001 Valid for credit through January 31, 2003 This activity has expired. CME in this activity indicates that it was developed according to ACCME guidelines and was certified for credit by one or more accredited CME or CE providers. Medscape cannot attest to the timeliness of expired CME activities. Contents of This CME Activity Myelodysplastic Syndromes Historical Background of Myelodysplastic Syndromes Classification of Myelodysplastic Syndromes Treatment of Myelodysplastic Syndromes Cytokines for Patients With Myelodysplastic Syndromes? Differentiating Agents New Agents in Development Summary References The material presented here does not reflect the views of Medical Education Collaborative, Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing medical education activity. Target Audience Learning Objectives Faculty and Disclosures Accreditation Statements ... Privacy and Confidentiality CME in this activity indicates continuing education for medical professionals.

8. THE MYELODYSPLASTIC SYNDROMES FOUNDATION 2001, Orlando, Florida. Involvement of the LymphoMyeloid Stem Cells in Different Cytogenetic Subgroups of myelodysplastic syndromes; http://www.mds-foundation.org/abstracts.htm

IN MEMORIUM Abstracts Selected Abstracts from the American Society of Hematology, December 2001, Orlando, Florida Involvement of the Lympho-Myeloid Stem Cells in Different Cytogenetic Subgroups of Myelodysplastic Syndromes The Evolving Ethical Dilemma of Low Dose Melphalan Chemotherapy in Advanced MDS/AML: Quality of Life in Remission Versus Predictable Induction of 17P Deletion Resolving Complex Aberrant Karyotypes in MDS and AML Evolving From MDS With 24-Color-FISH: A Study of 40 Cases Do Patients With Low-Grade Myelodysplastic Syndrome Mobilise Normal Hemopoietic Progenitors? ... Secondary Myelodysplastic Syndromes Following Treatment With Azathioprine Selected Abstracts from the Sixth International Symposium. (Spring 2001) Meeting Report: Fifth International Symposium on Myelodysplastic Syndromes Selected Abstracts from the American Society of Hematology, December 2000, San Francisco, California Biologic Determinants of Clinical Response to Thalidomide in Myelodysplasia Thalidomide as a Single Agent or in Combination with Topotecan, Pentoxifylline and/or Enbrel in Myelodysplastic Syndromes (MDS)

9. Aplastic Anemia & Myelodysplastic Syndromes International Foundation, Inc. - Ser AAMDS's mission is to serve as a resource directory for patient assistance and emotional support; provide educational materials and updated medical information; and financially support research to find effective treatments for aplastic anemia and myelodysplastic syndromes. http://www.aamds.org

In The News - Updates on diseases and treatments. Frequently Asked Questions Want to Talk? - Network with other patients and families. Enroll in our Patient Registry to help researchers compile data on these diseases Merchandise Purchases help Fight AA and MDS Collaborative Clinical Trials Study Group You are Visitor No: P.O. Box 613 Annapolis, Maryland 21404-0613 USA Tel: 800.747.2820 Fax 410.867.0240 E-Mail help@aamds.org We subscribe to the HONcode principles of the Health On the Net Foundation This site was selected for inclusion in Current Web Contents , published by ISI (Institute for Scientific Information); and MedlinePlus Health Information , published by NLM (National Library of Medicine). Site designed, marketed and maintained by

10. M. D. Anderson Cancer Center - Leukemia Department Overview of the various Leukemia and myelodysplastic syndromes, with information about treatment options. http://www.mdanderson.org/departments/leukemia/

Care Center Information A to Z Department List Breast Center Cancer Prevention Cardiopulmonary Gastrointestinal Genitourinary Gynecologic Oncology Internal Medicine Plastic Surgery Radiation Treatment Sarcoma Thoracic Alopecia Areata Angiogenesis Inhibitors Aplastic Anemia Basal/Squamous Cell Carcinomas Bladder Blood Stem Cell Transplant Bone Cancer Bone Marrow Failure (pediatric) Bone Marrow Transplants Brain Brain Tumors (pediatric) Breast Cancer Burkitt's Lymphoma Cancer Survivorship Carcinoid Tumors Cardiovascular Diseases Central Nervous System Cervical Chemoprevention Chest Wall and Sternal Tumors Childhood Cancers Colorectal Complementary/Integrative/Alt Med Dermatology - General Endometrial Esophageal Ewing's Sarcoma - pediatric Eye Cancers Eyelid/Orbital Tumors Fallopian Tube Germ Cell Tumors (pediatric) Gestational Trophoblastic Disease Graft Vs. Host Disease (GVHD) Head and Neck Cancers Hematologic Malignancies Hereditary Gynecologic Cancers Hodgkin's Disease Hodgkin's Disease (pediatric) Idiopathic Hypereosinophilic Synd Kidney Larynx Leptomeningeal Disease Leukemia Leukemia (pediatric) Liver Cancer Lung Lymphoblastic Lymphoma Lymphoma Lymphoma - Cutaneous T-Cell Mediastinal Tumors Medulloblastoma (pediatric) Melanoma Melanoma (eye) Melanoma (head and neck area) Mesothelioma Myelodysplastic Syndrome Myeloma - Multiple Nasopharynx Neuroblastoma (pediatric) Neurofibromatosis (pediatric) Non-Hodgkin's Lymph. (pediatric)

11. EMedicine - Myelodysplastic Syndrome : Article By Emmanuel C Besa, MD Myelodysplastic Syndrome. Aguayo A, Kantarjian H, Manshouri T, et al Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. http://www.emedicine.com/MED/topic2695.htm

(advertisement) Home Specialties CME PDA ... Patient Education Articles Images CME Patient Education Advanced Search Link to this site Back to: eMedicine Specialties Medicine, Ob/Gyn, Psychiatry, and Surgery Hematology Myelodysplastic Syndrome Last Updated: April 8, 2002 Rate this Article Email to a Colleague Synonyms and related keywords: MDS, preleukemia, refractory anemia, refractory dysmyelopoietic anemia, smoldering leukemia, subacute myelogenous leukemia, dysmyelopoiesis, refractory anemia, RA, RA with ringed sideroblasts, RARS, RA with excess blasts, RAEB, RAEB in transformation, RAEB-T AUTHOR INFORMATION Section 1 of 11 Author Information Introduction Clinical Differentials ... Bibliography Author: Emmanuel C Besa, MD , Professor, Department of Internal Medicine, Division of Hematology and Oncology, Drexel University College of Medicine Coauthor(s): Ulrich Woermann, MD , Consulting Staff, Division of Instructional Media, Institute for Medical Education, University of Bern, Switzerland Emmanuel C Besa, MD, is a member of the following medical societies:

12. Myelodysplastic Syndromes myelodysplastic syndromes. Bruce M. Small, M.D. State University of New York at Buffalo. I. predicting survival and planning treatment in myelodysplastic syndromes A multivariate analysis of prognostic factors http://www.smbs.buffalo.edu/med/mds.html

Myelodysplastic Syndromes Bruce M. Small, M.D. State University of New York at Buffalo I. The term "dysmyelopoietic or myelodysplastic syndrome" refers to a qualitative and quantitative abnormality of hematopoietic cells, sometimes progressing to acute leukemia. Specifically excluded are dyshematopoietic states with a well-understood, reversible basis such as B12 or folate deficiency. II. FAB classification - an attempt to systematize the recognition of preleukemic subtypes A. History 1. Before FAB, the term "preleukemia" was used to refer to a myeloproliferative disorder which preceded the development of acute leukemia. The definition excluded certain groups at high risk, such as Downs' syndrome, irradiated patients, polycythemia vera, myelofibrosis, CML, etc. 2. Since acute leukemia was not an inevitable development in those diagnosed with preleukemia, and since the term encompassed a wide clinical variation, it was necessary to refine our understanding of these diseases. Thus, the FAB classification. B. FAB distinguishes two groups on the basis of marrow cellularity

13. EMedicine - Myelodysplastic Syndrome : Article By Glenda H Grawe, MD clone to GMCSF and (2) reports on association of use of G-CSF in children with severe aplastic anemia and later development of myelodysplastic syndromes or AML http://www.emedicine.com/ped/topic1527.htm

(advertisement) Home Specialties CME PDA ... Patient Education Articles Images CME Patient Education Advanced Search Link to this site Back to: eMedicine Specialties Pediatrics Oncology Myelodysplastic Syndrome Last Updated: September 27, 2002 Rate this Article Email to a Colleague Synonyms and related keywords: MDS, chronic myelomonocytic leukemia, CMML clonal hemopathy, juvenile chronic myeloid leukemia, JCML, juvenile myelomonocytic leukemia, JMML, monosomy 7, oligoblastic leukemia, preleukemia, refractory anemia, RA, smoldering acute leukemia, acute myelogenous leukemia, AML, adult-type MDS, a-MDS, refractory anemia with ringed sideroblasts, RARS, refractory anemia with excess blasts, RAEB, refractory anemia with excess blasts in transition to AML, RAEBT, cytopenia AUTHOR INFORMATION Section 1 of 9 Author Information Introduction Clinical Differentials ... Bibliography Author: Glenda H Grawe, MD , Consulting Staff, Department of Medicine, Children's Hospitals and Clinics of Minneapolis, MN Coauthor(s): Timothy Cripe, MD, PhD

14. Society Disease Information - Myelodysplastic Syndromes About the Diseases myelodysplastic syndromes. print page myelodysplastic syndromes (MDS) are a group of diseases that originate in an early bloodforming cell in the marrow http://www.leukemia-lymphoma.org/all_page?item_id=55445

15. Cancer.gov - URL Changed General information, cellular classification, stage information, treatment options, de nova, secondary and previously treated myelodysplastic syndromes. http://cancernet.nci.nih.gov/cgi-bin/srchcgi.exe?TYPE=search&ZUI=208_02495P&

16. Myelodysplastic Syndrome Hub Links to information and resources for myelodysplastic syndromes. http://www.knowdeep.org/myelodysplastic

Myelodysplastic syndromes are a group of diseases in which the bone marrow does not function normally and not enough normal blood cells are made. They are fatal disorders which lead to death either through bone marrow failure or by transformation to leukemia. Myelodysplastic Syndrome by National Center Institute Cytogenetic and Molecular Evaluation in Myelodysplastic Syndrome and in Acute and Chronic Leukemia - by Peter R. Papenhausen, PhD, Lynn C. Moscinski, MD, and Cameron G. Binnie, PhD. Stanford Myelodysplastic Syndrome (MDS) Center - under the direction of Dr. Peter Greenberg, Professor of Medicine/Hematology. Myelodysplastic Syndrome from eMedicine - by Emmanuel C Besa, MD, Professor, Department of Internal Medicine, Division of Hematology and Oncology, Medical College of Pennsylvania Hahnemann University. Myelodysplasia at Johns Hopkins Aplastic Anemia, Myelodysplastic Syndrome, and Paroxysmal Nocturnal Hemoglobinuria (PNH) - by the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Analysis of Myelodysplastic Syndrome Clones Arising After Multiple Myeloma - a case study by correlative interphase cytogenetic analysis by Yukio Kobayashi, Michihiro Nakayama, Naoki Uemura, Kunihiko Takeyama, Kensei Tobinai, Takeaki Takenaka, Soon Hee Choi, Hitoshi Satoh, Shigeo Mori and Shigetaka Asano.

17. ClinicalTrials.gov - Information On Clinical Trials And Human Research Studies: TransfusionDependent myelodysplastic syndromes and a Cytogenetic novo myelodysplastic syndromes; previously treated myelodysplastic syndromes; secondary myelodysplastic syndromes http://clinicaltrials.gov/ct/screen/BrowseAny?path=/browse/by-condition/hier/BC1

18. Practice Guidelines In Oncology myelodysplastic syndromesVersion 1.2004, 10/27/03 © 2003 National Comprehensive 2004ContinueMyelodysplastic. SyndromesVersion 1.2004myelodysplastic syndromesVersion 1.2004, 10 http://www.nccn.org/physician_gls/PDF/mds.pdf

19. Myelodysplastic Syndromes Treatment statement for Health professionals. myelodysplastic syndromes. myelodysplastic syndromes Comparison of the FAB and WHO Classifications. http://www.meb.uni-bonn.de/cancer.gov/CDR0000062929.html

Treatment statement for Health professionals Myelodysplastic Syndromes Get this document via a secure connection General Information Classification Treatment Option Overview ... More Information General Information The myelodysplastic syndromes (MDS) are a group of disorders characterized by 1 or more peripheral blood cytopenias secondary to bone marrow dysfunction. The syndromes may arise de novo, or secondarily after treatment with chemotherapy and/or radiation therapy for other diseases. Secondary myelodysplasia usually has a poorer prognosis than does de novo myelodysplasia. Prognosis is directly related to the number of bone marrow blast cells and to the degree of peripheral blood cytopenias. The MDS transform to acute myeloid leukemia (AML) in about 30% of patients after various intervals from diagnosis, and at variable rates (refer to the Cellular Classification section for more information). The acute leukemic transformation is much less responsive to chemotherapy than is de novo AML. Prognosis is also related to the type of myelodysplastic syndrome. Supportive care has been the mainstay of treatment. Judicious use of platelet and blood transfusions and iron chelation may prevent or delay alloimmunization and iron overload, and favorably affect prognosis. The MDS are characterized by abnormal bone marrow and blood cell morphology. Megaloblastic erythroid hyperplasia with macrocytic anemia associated with normal B12 and folate levels is frequently observed. Circulating granulocytes are frequently severely reduced in number, often hypogranular or hypergranular, and may display the acquired pseudo-Pelger-Huet abnormality. Early, abnormal myeloid progenitors are identified in the marrow in varying percentages, depending on the type of myelodysplastic syndrome. Abnormally small megakaryocytes (micromegakaryocytes) are seen in the marrow and hypogranular or giant platelets appear in the blood.

20. Myelodysplastic Syndromes patient information myelodysplastic syndromes. myelodysplastic syndromes The myelodysplastic syndromes (MDS) are a group of diseases in which the production of blood cells is http://ds.dial.pipex.com/lrf-/diseases/mds.htm

home patient information myelodysplastic syndromes Myelodysplastic syndromes Leukaemia Research Fund produces a booklet on The Myelodysplastic Syndromes, which provides general information on the disease. To download this booklet as a PDF click here . To view a copy of this booklet click here Useful links for health professionals Patient publications on the web Reviews Key information Teaching aids ... Scientific meetings The myelodysplastic syndromes (MDS) are a group of diseases in which the production of blood cells is severely disrupted. The term myelodysplasia may be used to refer to the effects of myelodysplastic syndrome on the bone marrow. In contrast to leukaemia in which one type of blood cell is produced in excessively large numbers the production of any, and sometimes of all, types of blood cells is affected in myelodysplastic syndrome. Synonyms: Refractory Anaemia; Preleukaemia; Chronic Myelomonocytic Leukaemia

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 1     1-20 of 97    1  | 2  | 3  | 4  | 5  | Next 20